Gastrointestinal Therapeutics in Major Developed Markets to 2019 - New Drug Approvals and Promising Pipeline to Counter Declines from Patent Expiries

Publisher Name :
Date: 27-Jan-2014
No. of pages: 90

GBI Research, the leading business intelligence provider, has released its latest research, ‘Gastrointestinal Therapeutics in Major Developed Markets to 2019 New Drug Approvals and Promising Pipeline to Counter Declines from Patent Expiries’, which provides insights into three gastrointestinal therapeutic indications in the major developed markets of the US, the UK, France, Germany, Italy, Spain, Japan and Canada. The report provides an in-depth analysis of three gastrointestinal therapeutics markets, namely Irritable Bowel Syndrome (IBS), Ulcerative Colitis (UC) and Crohn’s Disease (CD). The report provides an estimation of market size for 2012, along with market forecast until 2019. It also covers disease epidemiology, treatment algorithms, treatment patterns, in-depth analysis of the pipeline, and deal analysis for these three gastrointestinal indications.

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis carried out by GBI Research’s team of industry experts.

In 2012, the value of the gastrointestinal therapeutics market in major developed countries amounted to an estimated $6.8 billion. This total is forecast to decline at a Compound Annual Growth Rate (CAGR) of 0.3% between 2012 and 2019. The value of the IBS market amounted to an estimated $727m, and is forecast to increase at a CAGR of 14.4% between 2012 and 2019. The value of the UC market amounted to an estimated $2.2 billion in 2012, and is expected to increase at a CAGR of 6% during the forecast period. The value of the CD market amounted to an estimated $3.8 billion, which is expected to decline at a CAGR of 7.5% between 2012 and 2019.

Scope


  • The report analyzes treatment usage patterns, market characterization, pipeline analysis and key licensing and co-development deals for the IBS, UC and CD indications in the major developed markets of the US, the UK, France, Germany, Italy, Spain, Japan and Canada.

  • Disease overview and treatment usage patterns

  • Market size and forecast for IBS, UC and CD in major developed markets from 2012 to 2019

  • Major marketed products for the indication types covered

  • In-depth pipeline analysis for IBS, UC and CD

  • Key drivers and restraints that have had and are expected to have a major impact upon the market

  • Key licensing and co-development agreements in the gastrointestinal therapeutics market


Reasons to buy

  • Align your product portfolio to the markets with high growth potential

  • Develop market entry and expansion strategies by identifying the potential regions and therapeutic segments that are poised for strong growth

  • Devise a more effectively tailored country-specific strategy through the understanding of key drivers and barriers in the gastrointestinal therapeutics market

  • Develop key strategic initiatives based upon an understanding of key focus areas and leading companies

  • Accelerate and strengthen your market position by identifying key companies for mergers, acquisitions and strategic partnerships

Gastrointestinal Therapeutics in Major Developed Markets to 2019 - New Drug Approvals and Promising Pipeline to Counter Declines from Patent Expiries

Table of Contents

1 Table of Contents 6
1.1 List of Tables 9
1.2 List of Figures 10

2 Gastrointestinal Therapeutics in Major Developed Markets – Introduction 11
2.1 Irritable Bowel Syndrome 11
2.1.1 Classification 11
2.1.2 Symptoms 11
2.1.3 Etiology 11
2.1.4 Pathophysiology 12
2.1.5 Diagnosis 12
2.1.6 Epidemiology 13
2.1.7 Prognosis 14
2.1.8 Treatment Options 14
2.2 Ulcerative Colitis 15
2.2.1 Classification 15
2.2.2 Symptoms 16
2.2.3 Etiology 16
2.2.4 Pathophysiology 17
2.2.5 Diagnosis 17
2.2.6 Epidemiology 18
2.2.7 Prognosis 18
2.2.8 Treatment Options 19
2.3 Crohn’s Disease 20
2.3.1 Classification 20
2.3.2 Symptoms 21
2.3.3 Etiology 21
2.3.4 Pathophysiology 22
2.3.5 Diagnosis 22
2.3.6 Epidemiology 23
2.3.7 Prognosis 23
2.3.8 Treatment Options 24

3 Gastrointestinal Therapeutics in Major Developed Markets – Marketed Products (Global) 25
3.1 Irritable Bowel Syndrome 25
3.2 Ulcerative Colitis 25
3.3 Crohn’s Disease 25
3.4 Key Marketed Products 26
3.4.1 Amitiza 26
3.4.2 Humira 27
3.4.3 Remicade 28
3.4.4 Simponi 29
3.4.5 Cimzia 30
3.4.6 Tysabri 31

4 Gastrointestinal Therapeutics in Major Developed Markets – Pipeline Analysis 33
4.1 Irritable Bowel Syndrome 33
4.1.1 Overall Pipeline 33
4.1.2 Pipeline Analysis by Molecule Type 35
4.1.3 Pipeline Analysis by Mechanism of Action 36
4.2 Ulcerative Colitis Pipeline 38
4.2.1 Overall Pipeline 38
4.2.2 Pipeline Analysis by Molecule Type 40
4.2.3 Pipeline Analysis by Mechanism of Action 41
4.3 Crohn’s Disease Pipeline 43
4.3.1 Overall Pipeline 43
4.3.2 Pipeline Analysis by Molecule Type 45
4.3.3 Pipeline Analysis by Mechanism of Action 46
4.4 Promising Drug Candidates in the Pipeline 48
4.4.1 GSK-1605786 48
4.4.2 MLN0002 48
4.4.3 EMD-61753 48

5 Gastrointestinal Therapeutics in Major Developed Markets – Market Forecast to 2019 49
5.1 Major Developed Markets 49
5.1.1 Treatment Usage Patterns 49
5.1.2 Annual Cost of Therapy 49
5.1.3 Market Size 49
5.2 US 51
5.2.1 Treatment Usage Patterns 51
5.2.2 Annual Cost of Therapy 51
5.2.3 Market Size 51
5.3 Europe 53
5.3.1 Treatment Usage Patterns 53
5.3.2 Annual Cost of Therapy 53
5.3.3 Market Size 53
5.4 Canada 55
5.4.1 Treatment Usage Patterns 55
5.4.2 Annual Cost of Therapy 55
5.4.3 Market Size 55
5.5 Japan 57
5.5.1 Treatment Usage Patterns 57
5.5.2 Annual Cost of Therapy 57
5.5.3 Market Size 57
5.6 Drivers and Barriers 59
5.6.1 Drivers 59
5.6.2 Barriers 59

6 Gastrointestinal Therapeutics in Major Developed Markets – Deals and Strategic Consolidations (Global) 61
6.1 Deals Analysis 61
6.2 Major Co-Development Deals 63
6.2.1 AstraZeneca Enters into Co-Development Agreement with Ironwood Pharma for Linaclotide 64
6.2.2 Amgen Enters into Co-development Agreement with AstraZeneca for Five Monoclonal Antibodies 64
6.2.3 Galapagos and AbbVie Extend GLPG0634 Development Agreement to Include Crohn's Disease 64
6.3 Major Licensing Deals 65
6.3.1 AstraZeneca Enters into Licensing Agreement with Ardelyx for NHE3 Inhibitor Program 66
6.3.2 Sanofi-Aventis Enters into Licensing Agreement with Kyowa Hakko Kirin 66
6.3.3 GlaxoSmithKline Enters into Licensing Agreement with ChemoCentryx 66

7 Gastrointestinal Therapeutics in Major Developed Markets – Appendix 67
7.1 All Pipeline Drugs by Phase 67
7.1.1 Discovery 67
7.1.2 Preclinical 67
7.1.3 IND/CTA-filed 68
7.1.4 Phase I 69
7.1.5 Phase II 70
7.1.6 Phase III 72
7.1.7 Pre-Registration 72
7.1.8 Undisclosed 73
7.2 Market Forecasts to 2019 73
7.2.1 Major Developed Markets 73
7.2.2 US 74
7.2.3 Canada 75
7.2.4 UK 76
7.2.5 France 77
7.2.6 Germany 78
7.2.7 Italy 79
7.2.8 Spain 80
7.2.9 Japan 81
7.3 Market Definitions 82
7.4 Abbreviations 82
7.5 Sources 84
7.6 Research Methodology 86
7.6.1 Coverage 86
7.6.2 Secondary Research 86
7.6.3 Primary Research 87
7.6.4 Therapeutic Landscape 87
7.6.5 Geographical Landscape 90
7.6.6 Pipeline Analysis 90
7.7 Expert Panel Validation 90
7.8 Contact Us 90
7.9 Disclaimer 90

List of Tables

Table 1: Gastrointestinal Therapeutics Market, Irritable Bowel Syndrome, Classification, 2009 11
Table 2: Gastrointestinal Therapeutics Market, Major Developed Markets, Treatment Recommendations for Irritable Bowel Syndrome, 2009 15
Table 3: Gastrointestinal Therapeutics Market, Major Developed Markets, Classification of Ulcerative Colitis, 2004 15
Table 4: Gastrointestinal Therapeutics Market, Major Developed Markets, Diagnosis of Ulcerative Colitis, 2007 17
Table 5: Gastrointestinal Therapeutics Market, Major Developed Markets, Difference Between Ulcerative Colitis and Crohn’s Disease, 2007 18
Table 6: Gastrointestinal Therapeutics Market, Major Developed Markets, Treatment Options of Ulcerative Colitis, 2011 20
Table 7: Gastrointestinal Therapeutics Market, Major Developed Markets, Classification of Crohn’s Disease, 2013 20
Table 8: Gastrointestinal Therapeutics Market, Major Developed Markets, Symptoms of Crohn’s Disease, 2012 21
Table 9: Gastrointestinal Therapeutics Market, Major Developed Markets, Treatment Options for Crohn’s Disease , 2009 24
Table 10: Gastrointestinal Therapeutics Market, Global, Pipeline (Discovery), 2013 67
Table 11: Gastrointestinal Therapeutics Market, Global, Pipeline (Preclinical), 2013 67
Table 12: Gastrointestinal Therapeutics Market, Global, Pipeline (IND/CTA-filed), 2013 68
Table 13: Gastrointestinal Therapeutics Market, Global, Pipeline (Phase I), 2013 69
Table 14: Gastrointestinal Therapeutics Market, Global, Pipeline (Phase II), 2013 70
Table 15: Gastrointestinal Therapeutics Market, Global, Pipeline (Phase III), 2013 72
Table 16: Gastrointestinal Therapeutics Market, Global, Pipeline (Pre-Registration), 2013 72
Table 17: Gastrointestinal Therapeutics Market, Global, Pipeline (Undisclosed), 2012 73
Table 18: Gastrointestinal Therapeutics Major Developed Markets, Irritable Bowel Syndrome, Market Forecast, 2012–2019 73
Table 19: Gastrointestinal Therapeutics Market, Major Developed Markets, Ulcerative Colitis, Market Forecast, 2012–2019 74
Table 20: Gastrointestinal Therapeutics Market, Major Developed Markets, Crohn’s Disease, Market Forecast, 2012–2019 74
Table 21: Gastrointestinal Therapeutics Market, US, Irritable Bowel Syndrome, Market Forecast, 2012–2019 74
Table 22: Gastrointestinal Therapeutics Market, US, Ulcerative Colitis, Market Forecast, 2012–2019 75
Table 23: Gastrointestinal Therapeutics Market, US, Crohn’s Disease, Market Forecast, 2012–2019 75
Table 24: Gastrointestinal Therapeutics Market, Canada, Irritable Bowel Syndrome, Market Forecast, 2012–2019 75
Table 25: Gastrointestinal Therapeutics Market, Canada, Ulcerative Colitis, Market Forecast, 2012–2019 76
Table 26: Gastrointestinal Therapeutics Market, Canada, Crohn’s Disease, Market Forecast, 2012–2019 76
Table 27: Gastrointestinal Therapeutics Market, UK, Irritable Bowel Syndrome, Market Forecast, 2012–2019 76
Table 28: Gastrointestinal Therapeutics Market, UK, Ulcerative Colitis, Market Forecast, 2012–2019 77
Table 29: Gastrointestinal Therapeutics Market, UK, Crohn’s Disease, Market Forecast, 2012–2019 77
Table 30: Gastrointestinal Therapeutics Market, France, Irritable Bowel Syndrome, Market Forecast, 2012–2019 77
Table 31: Gastrointestinal Therapeutics Market, France, Ulcerative Colitis, Market Forecast, 2012–2019 78
Table 32: Gastrointestinal Therapeutics Market, France, Crohn’s Disease, Market Forecast, 2012–2019 78
Table 33: Gastrointestinal Therapeutics Market, Germany, Irritable Bowel Syndrome, Market Forecast, 2012–2019 78
Table 34: Gastrointestinal Therapeutics Market, Germany, Ulcerative Colitis, Market Forecast, 2012–2019 79
Table 35: Gastrointestinal Therapeutics Market, Germany, Crohn’s Disease, Market Forecast, 2012–2019 79
Table 36: Gastrointestinal Therapeutics Market, Italy, Irritable Bowel Syndrome, Market Forecast, 2012–2019 79
Table 37: Gastrointestinal Therapeutics Market, Italy, Ulcerative Colitis, Market Forecast, 2012–2019 80
Table 38: Gastrointestinal Therapeutics Market, Italy, Crohn’s Disease, Market Forecast, 2012–2019 80
Table 39: Gastrointestinal Therapeutics Market, Spain, Irritable Bowel Syndrome, Market Forecast, 2012–2019 80
Table 40: Gastrointestinal Therapeutics Market, Spain, Ulcerative Colitis, Market Forecast, 2012–2019 81
Table 41: Gastrointestinal Therapeutics Market, Spain, Crohn’s Disease, Market Forecast, 2012–2019 81
Table 42: Gastrointestinal Therapeutics Market, Japan, Irritable Bowel Syndrome, Market Forecast, 2012–2019 81
Table 43: Gastrointestinal Therapeutics Market, Japan, Ulcerative Colitis, Market Forecast, 2012–2019 82
Table 44: Gastrointestinal Therapeutics Market, Japan, Crohn’s Disease, Market Forecast, 2012–2019 82

List of Figures

Figure 1: Gastrointestinal Therapeutics Market, Major Developed Markets, Treatment Algorithm of Ulcerative Colitis, 2007 19
Figure 2: Gastrointestinal Therapeutics Market, Global, Sales of Amitiza ($m), 2006–2012 26
Figure 3: Gastrointestinal Therapeutics Market, Global, Sales of Humira ($bn), 2006–2012 27
Figure 4: Gastrointestinal Therapeutics Market, Global, Sales of Remicade ($bn), 2006–2012 28
Figure 5: Gastrointestinal Therapeutics Market, Global, Sales of Simponi ($m), 2009–2012 29
Figure 6: Gastrointestinal Therapeutics Market, Global, Sales of Cimzia ($m), 2008–2012 30
Figure 7: Gastrointestinal Therapeutics Market, Global, Sales of Tysabri ($m), 2006–2012 31
Figure 8: Gastrointestinal Therapeutics Market, Global, Irritable Bowel Syndrome, Pipeline, 2013 34
Figure 9: Gastrointestinal Therapeutics Market, Global, Irritable Bowel Syndrome, Pipeline by Molecule Type, 2013 35
Figure 10: Gastrointestinal Therapeutics Market, Global, Irritable Bowel Syndrome, Pipeline by Mechanism of Action, 2012 37
Figure 11: Gastrointestinal Therapeutics Market, Global, Ulcerative Colitis, Pipeline, 2013 39
Figure 12: Gastrointestinal Therapeutics Market, Global, Ulcerative Colitis, Pipeline by Molecule Type, 2013 40
Figure 13: Gastrointestinal Therapeutics Market, Global, Ulcerative Colitis, Pipeline by Mechanism of Action, 2013 42
Figure 14: Gastrointestinal Therapeutics Market, Global, Crohn’s Disease, Pipeline, 2013 44
Figure 15: Gastrointestinal Therapeutics Market, Global, Crohn’s Disease, Pipeline by Molecule Type, 2013 45
Figure 16: Gastrointestinal Therapeutics Market, Global, Crohn’s Disease, Pipeline by Mechanism of Action, 2013 47
Figure 17: Gastrointestinal Therapeutics Market, Major Developed Markets, Market Size ($bn), 2012–2019 50
Figure 18: Gastrointestinal Therapeutics Market, US, Market Size ($bn), 2012–2019 52
Figure 19: Gastrointestinal Therapeutics Market, Top Five European Countries, Market Size ($bn), 2012–2019 54
Figure 20: Gastrointestinal Therapeutics Market, Canada, Market Size ($m), 2012–2019 56
Figure 21: Gastrointestinal Therapeutics Market, Japan, Market Size ($m), 2012–2019 58
Figure 22: Gastrointestinal Therapeutics Market, Global, Deals, 2006–2013 62
Figure 23: Gastrointestinal Therapeutics Market, Global, Co-Development Deals, 2006–2013 63
Figure 24: Gastrointestinal Therapeutics Market, Global, Licensing Deals, 2006–2013 65
Figure 25: GBI Research Market Forecasting Model 89

  • Global Gastroparesis Drugs Market Size, Status and Forecast 2019-2025
    Published: 18-Jan-2019        Price: US 3900 Onwards        Pages: 99
    Gastroparesis also known as delayed gastric emptying, is a disorder that stops or slows the movement of food through the digestive tract. The idiopathic gastroparesis segment dominated the global gastroparesis drugs market during 2017 and the segment is expected to continue its dominance during the next few years as well. The market is witnessing the development of new and effective therapies for the symptomatic control of idiopathic gastroparesis, which will be one of the major factors r......
  • Global Gastrointestinal OTC Drugs Market Size, Status and Forecast 2019-2025
    Published: 18-Jan-2019        Price: US 3900 Onwards        Pages: 90
    Gastrointestinal OTC drugs are used for indications such as GERD, vomiting, constipation, diarrhea, and flatulence. Some of the OTC drugs that are available for the treatment of gastrointestinal diseases are laxatives, anti-flatulents, H2-antaginists, anti-diarrheals, PPIs, and anti-emetics. The OTC drugs are not bound by regulatory guidelines, but need to comply with the drug monograph of a country. In 2018, the global Gastrointestinal OTC Drugs market size was xx million US$ and it is e......
  • Anti Peptic Ulcer Drugs Markets in China
    Published: 17-Jan-2019        Price: US 4000 Onwards        Pages: 211
    China's demand for Anti Peptic Ulcer Drugs has grown at a fast pace in the past decade. In the next decade, both production and demand will continue to grow. The Chinese economy maintains a high speed growth which has been stimulated by the consecutive increases of industrial output, import & export, consumer consumption and capital investment for over two decades. This new study examines China's economic trends, investment environment, industry development, supply and demand, industry capacity,......
  • Anti Peptic Ulcer Drugs Companies in China
    Published: 17-Jan-2019        Price: US 1800 Onwards        Pages: 54
    This study focuses on China's Anti Peptic Ulcer Drugs industry assessments and company profiles. In the two past decades, the industry has been growing at a fast pace. The dramatic expansions of the manufacturing capabilities and rising consumer consumptions in China have transformed China's society and economy. China is one of the world's major producers for industrial and consumer products. Far outpacing other economies in the world, China is the world's fastest growing market for the consumpt......
  • Anti Peptic Ulcer Drugs Industry Forecasts - China Focus
    Published: 17-Jan-2019        Price: US 1800 Onwards        Pages: 107
    This study focuses on China's Anti Peptic Ulcer Drugs industry forecasts. In the two past decades, the industry has been growing at a fast pace. The dramatic expansions of the manufacturing capabilities and rising consumer consumptions in China have transformed China's society and economy. China is one of the world's major producers for industrial and consumer products. Far outpacing other economies in the world, China is the world's fastest growing market for the consumptions of goods and servi......
  • Global Exocrine Pancreatic Insufficiency Market Size, Status and Forecast 2019-2025
    Published: 17-Jan-2019        Price: US 3900 Onwards        Pages: 95
    Exocrine pancreatic insufficiency (EPI) is an inability of proper digestion of food owing to insufficient levels of digestive enzymes from pancreas. EPI is commonly found in humans affected with Shwachman-Diamond Syndrome and cystic fibrosis. EPI is triggered by the progressive loss of pancreatic cells, which generates the digestive enzymes. EPI disturbs the normal growth, life expectancy and immune response. Diarrhoea, Steatorrhea, fatigue and weight loss are the key symptoms of EPI.......
  • Helicobacter Pylori Infections - Market Insight, Epidemiology and Market Forecast - 2028
    Published: 15-Jan-2019        Price: US 6250 Onwards        Pages: 100
    DelveInsight's "Helicobacter Pylori Infections - Market Insight, Epidemiology and Market Forecast - 2028" report provides a detailed analysis of the Helicobacter Pylori Infections epidemiology and market outlook for the 7MM. Markets Covered - United States - EU5 (Germany, France, Italy, Spain, and the United Kingdom) - Japan Study Period: 2016-2028 Helicobacter Pylori Infections Understanding and Treatment Algorithm The mar......
  • Short Bowel Syndrome - Epidemiology Forecast to 2028
    Published: 15-Jan-2019        Price: US 3250 Onwards        Pages: 50
    DelveInsight's "Short Bowel Syndrome - Epidemiology Forecast, 2028" report provides a comprehensive analysis of the Short Bowel Syndrome epidemiology, providing the historical and forecasted data for the 7MM during the forecast period from 2016-2028. Markets Covered - United States - EU5 (Germany, France, Italy, Spain, and the United Kingdom) - Japan Study Period: 2016-2028 Short Bowel Syndrome Epidemiology The epidemiology......
  • Exocrine Pancreatic Insufficiency - Pipeline Insight, 2019
    Published: 15-Jan-2019        Price: US 1250 Onwards        Pages: 50
    "Exocrine Pancreatic Insufficiency - Pipeline Insight, 2019" report by DelveInsight offers comprehensive Insight of the pipeline (under development) therapeutics scenario and growth prospects across Exocrine Pancreatic Insufficiency development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule ty......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs